NovoCure (NVCR) General Counsel adds 1,299 ESPP shares to holdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NovoCure Ltd General Counsel Ben Arye Barak acquired 1,299 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at 85% of the January 1, 2026 closing price, at a reported price of $11.15 per share, bringing his direct holdings to 243,752 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ben Arye Barak
Role
General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Ordinary Shares | 1,299 | $11.15 | $14K |
Holdings After Transaction:
Ordinary Shares — 243,752 shares (Direct, null)
Footnotes (1)
- The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Key Figures
ESPP shares acquired: 1,299 shares
Purchase price: $11.15 per share
Holdings after transaction: 243,752 shares
+1 more
4 metrics
ESPP shares acquired
1,299 shares
Ordinary shares acquired on June 30, 2026 via 2025 ESPP
Purchase price
$11.15 per share
Price for ESPP acquisition of 1,299 ordinary shares
Holdings after transaction
243,752 shares
Total direct NovoCure ordinary shares held after ESPP purchase
ESPP discount rate
85% of closing price
Shares bought at 85% of January 1, 2026 closing price
Key Terms
Employee Share Purchase Plan, ESPP, Rule 16b-3(c), Form 4
4 terms
ESPP financial
"In accordance with the ESPP, these shares were purchased based on 85% of the closing price"
An Employee Stock Purchase Plan (ESPP) is a company program that lets employees buy the company’s shares at a reduced price, usually by setting aside a small portion of their pay over time. It matters to investors because it encourages employees to own part of the business—like giving staff a discounted membership— which can boost commitment and performance, while also potentially increasing the number of shares available and affecting shareholder value.
Rule 16b-3(c) regulatory
"This transaction is also exempt under Rule 16b-3(c)."
An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did NovoCure (NVCR) report for Ben Arye Barak?
NovoCure reported that General Counsel Ben Arye Barak acquired 1,299 ordinary shares. The shares were obtained through the 2025 Employee Share Purchase Plan for the January 1, 2026 to June 30, 2026 purchase period, increasing his direct holdings to 243,752 shares.
Is Ben Arye Barak’s NovoCure (NVCR) Form 4 transaction an open-market purchase?
No, the transaction is classified as a grant, award, or other acquisition under code A, via the 2025 Employee Share Purchase Plan. The shares were acquired at a discount formula tied to 85% of the January 1, 2026 closing price, not as an open-market trade.